Genotype-dependent impairment of hemoglobin clearance increases oxidative and inflammatory response in human diabetic atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2769-2775

  Purushothaman, Meerarani ^a   Krishnan, Prakash ^a   Purushothaman, K Raman ^a   Baber, Usman ^a   Tarricone, Arthur ^a   Perez, Juan S ^a   Wiley, Jose ^a   Kini, Annapoorna ^a   Sharma, Samin K ^a   Fuster, Valentin ^b   Moreno, Pedro R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Atherosclerosis; Diabetes mellitus; Haptoglobin; Inflammation; Oxidative stress

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD163 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HAPTOGLOBIN; HEME OXYGENASE 1; HEMOGLOBIN; HP2 2 PROTEIN; INSULIN; INTERLEUKIN 10; IRON; MYELOPEROXIDASE; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ACTA2 PROTEIN, HUMAN; ACTIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; HMOX1 PROTEIN, HUMAN; HP PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PEROXIDASE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ATHERECTOMY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD SAMPLING; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; GENE EXPRESSION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTENSION; INFLAMMATION; INSULIN TREATMENT; MACROPHAGE; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BLOOD; CASE CONTROL STUDY; DIABETIC ANGIOPATHY; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROSPECTIVE STUDY;

ACTINS; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; GENOTYPE; HAPTOGLOBINS; HEME OXYGENASE-1; HEMOGLOBINS; HUMANS; INFLAMMATION; INTERLEUKIN-10; IRON; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; PEROXIDASE; PHENOTYPE; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84871861524     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.252122     Document Type: Article

References (43)

1. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-2061.
2. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic ath-erothrombosis. J Am Coll Cardiol. 2004;44:2293-2300.
3. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neo-vascularization in human atherosclerosis. Circulation. 2006;113:2245-2252.
4. Pasterkamp G, van der Steen AF. Intraplaque hemorrhage: an imaging marker for atherosclerotic plaque destabilization? Arterioscler Thromb Vasc Biol. 2012;32:167-168.
5. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol. 2007;49:2073-2080.
6. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316-2325.
7. Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, Szentmiklósi J, Méhes G, Csonka T, Smith A, Vercellotti GM, Balla G, Balla J. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol. 2010;30:1347-1353.
8. Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, Moreno PR. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2007;27:134-140.
9. Herrmann J, Lerman LO, Mukhopadhyay D, Napoli C, Lerman A. Angiogenesis in atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:1948-1957.
10. Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR, Herman AG, Bult H. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:440-446.
11. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662.
12. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92:1193-1200.
13. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identifcation of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
14. Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol. 2002;34:309-314.
15. Morita T. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:1786-1795.
16. Kaempfer T, Duerst E, Gehrig P, Roschitzki B, Rutishauser D, Grossmann J, Schoedon G, Vallelian F, Schaer DJ. Extracellular hemoglobin polarizes the macrophage proteome toward Hb-clearance, enhanced antioxidant capacity and suppressed HLA class 2 expression. J Proteome Res. 2011;10:2397-2408.
17. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV; Strong Heart Study. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol. 2002;40:1984-1990.
18. Blum S, Milman U, Shapira C, Miller-Lotan R, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol. 2008;28:e18-e20.
19. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, Moreno PR. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res. 2007;101:106-110.
20. Purushothaman KR, Purushothaman M, Muntner P, Lento PA, O'Connor WN, Sharma SK, Fuster V, Moreno PR. Infammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis. Vasc Med. 2011;16:103-108.
21. Moreno PR, Purushothaman KR, Purushothaman M, Muntner P, Levy NS, Fuster V, Fallon JT, Lento PA, Winterstern A, Levy AP. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol. 2008;52:1049-1051.
22. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype-and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435-441.
23. Kalet-Litman S, Moreno PR, Levy AP. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis. 2010;209:28-31.
24. Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phe-notypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry. 2004;43:3899-3906.
25. Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macro-phages exposed to free hemoglobin. Atherosclerosis. 2007;191:48-53.
26. Levy AP, Asleh R, Blum S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal. 2010;12:293-304.
27. Lioupis C, Barbatis C, Drougou A, Koliaraki V, Mamalaki A, Klonaris C, Georgopoulos S, Andrikopoulos V, Bastounis E. Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis. 2011;216:131-138.
28. Finn AV, Nakano M, Polavarapu R, Karmali V, Saeed O, Zhao X, Yazdani S, Otsuka F, Davis T, Habib A, Narula J, Kolodgie FD, Virmani R. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59:166-177.
29. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC. Hemoglobin scavenger receptor CD163 mediates interleu-kin-10 release and heme oxygenase-1 synthesis: antiinfammatory mono-cyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004;94:119-126.
30. Feig JE, Vengrenyuk Y, Reiser V, Wu C, Statnikov A, Aliferis CF, Garabedian MJ, Fisher EA, Puig O. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS ONE. 2012;7:e39790.
31. Cheng C, Noordeloos AM, Jeney V, Soares MP, Moll F, Pasterkamp G, Serruys PW, Duckers HJ. Heme oxygenase 1 determines atherosclerotic lesion progression into a vulnerable plaque. Circulation. 2009;119:3017-3027.
32. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary infammation in unstable angina. N Engl J Med. 2002;347:5-12.
33. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
34. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102-1111.
35. Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes. 2008;57:2794-2800.
36. Tabas I. Macrophage death and defective infammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10:36-46.
37. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of infammation: state of the art, defnitions and terms. FASEB J. 2007;21:325-332.
38. Seljefot I, Hurlen M, Solheim S, Arnesen H. Serum levels of interleu-kin-10 are inversely related to future events in patients with acute myo-cardial infarction. J Thromb Haemost. 2004;2:350-352.
39. Simpson M, Snell-Bergeon JK, Kinney GL, Lache O, Miller-Lotan R, Anbinder Y, Rewers MJ, Levy AP. Haptoglobin genotype predicts development of coronary artery calcifcation in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol. 2011;10:99.
40. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care. 2003;26:2628-2631.
41. Suleiman M, Kapeliovich MR, Roguin A, Aronson D, Meisel SR, Shochat M, Reisner SA, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin type and 30-day mortality in diabetic individuals presenting with acute myocardial infarction. Diabetes Care. 2003;26:2699-2700.
42. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008;28:341-347.
43. Levy Y, Blum S, Levy AP. Antioxidants in the prevention of atherosclerosis: the importance of proper patient selection. Clin Nutr. 2009;28:581-582.